Interestingly, the activity of vitamin C against KRAS/BRAF mutated colorectal cancer might be useful to counteract tumor resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (i.e., cetuximab, panitumumab) [182]. The gene discussed is KRAS; the disease is colorectal cancer.